Capturing viral diversity for in-vitro test reagents and HIV vaccine immunogen design
暂无分享,去创建一个
[1] D. Nixon,et al. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides , 1988, Nature.
[2] D. Nickle,et al. Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope , 2005, Journal of Virology.
[3] Mario Roederer,et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.
[4] B. Walker,et al. The challenges of host and viral diversity in HIV vaccine design. , 2006, Current opinion in immunology.
[5] J. Mascola,et al. Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys , 2005, Journal of Virology.
[6] Todd M. Allen,et al. The Majority of Currently Circulating Human Immunodeficiency Virus Type 1 Clade B Viruses Fail To Prime Cytotoxic T-Lymphocyte Responses against an Otherwise Immunodominant HLA-A2-Restricted Epitope: Implications for Vaccine Design , 2005, Journal of Virology.
[7] S. Kent,et al. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. , 2005, Vaccine.
[8] O. Yang,et al. Detection of HIV-1-specific CTL responses in Clade B infection with Clade C Peptides and not Clade B consensus peptides. , 2005, Journal of immunological methods.
[9] J. Sidney,et al. Discovery and characterization of highly immunogenic and broadly recognized mimics of the HIV‐1 CTL epitope Gag77–85 , 2005, European journal of immunology.
[10] Andrew K. Sewell,et al. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA , 2005, The Journal of experimental medicine.
[11] B. Walker,et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.
[12] Todd M. Allen,et al. Enhanced Detection of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses to Highly Variable Regions by Using Peptides Based on Autologous Virus Sequences , 2003, Journal of Virology.
[13] Feng Gao,et al. Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.
[14] F. M. Marincola,et al. Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities , 2004, Journal of Virology.
[15] James Theiler,et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.
[16] David Heckerman,et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes , 2006, Nature Immunology.
[17] Feng Gao,et al. Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env Immunogen , 2006, Journal of Virology.
[18] A. Osterhaus,et al. Fluorescent antigen-transfected target cell cytotoxic T lymphocyte assay for ex vivo detection of antigen-specific cell-mediated cytotoxicity. , 2005, The Journal of infectious diseases.
[19] Alessandro Sette,et al. Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1 1 , 2003, The Journal of Immunology.
[20] Bette T. Korber,et al. Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein , 2005, Journal of Virology.
[21] Søren Brunak,et al. Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation , 2002, Journal of Virology.
[22] J. Kaplan,et al. Solid-Phase Epitope Recovery: A High Throughput Method for Antigen Identification and Epitope Optimization , 2002, The Journal of Immunology.
[23] Z. Weng,et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. , 2006, Virology.
[24] C. Katlama,et al. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. , 1996, Journal of immunology.
[25] B. Autran,et al. AIDS virus-specific cytotoxic T lymphocytes in lung disorders , 1987, Nature.
[26] Feng Gao,et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. , 2006, Virology.
[27] C. Williamson,et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. , 2006, The Journal of general virology.
[28] Galit Alter,et al. De Novo Generation of Escape Variant-Specific CD8+ T-Cell Responses following Cytotoxic T-Lymphocyte Escape in Chronic Human Immunodeficiency Virus Type 1 Infection , 2005, Journal of Virology.
[29] R. Shankarappa,et al. Minimization of genetic distances by the consensus, ancestral, and center-of-tree (COT) sequences for HIV-1 variants within an infected individual and the design of reagents to test immune reactivity. , 2006, Virology.
[30] Sarah Rowland-Jones,et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.
[31] L. Jagodzinski,et al. HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides , 2005, AIDS.
[32] D. Nickle,et al. Consensus and Ancestral State HIV Vaccines , 2003, Science.
[33] Feng Gao,et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. , 2007, Virology.
[34] Peter B Gilbert,et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. , 2006, Vaccine.